225
Participants
Start Date
May 26, 2023
Primary Completion Date
May 31, 2026
Study Completion Date
September 30, 2026
TNG462
TNG462, a selective PRMT5 inhibitor, will be administered orally
Pembrolizumab
An anti PD-1 antibody, will be administered intravenously
RECRUITING
New York University Langone Health, New York
RECRUITING
Next Oncology Virginia, Fairfax
RECRUITING
Hospital Universitario Fundacion Jimenez Diaz, Madrid
RECRUITING
Hospital de Sanchinarro, Madrid
RECRUITING
Hospital Universitario Virgen de la Victoria, Málaga
RECRUITING
CHU de Brest, Brest
RECRUITING
Sylvester Comprehensive Cancer Center, Miami
RECRUITING
Sarah Cannon Tennessee Oncology, Nashville
RECRUITING
Hospital Universitario Virgen del Rocio, Seville
RECRUITING
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS, Saint-Herblain
RECRUITING
Henry Ford Cancer Center, Detroit
RECRUITING
Midwestern Regional Medical Center, City of Hope Chicago, Zion
RECRUITING
University Chicago Medicine, Chicago
RECRUITING
Carle Cancer Center, Urbana
RECRUITING
Centre Berard Leon, Lyon
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Grand Valley Oncology, Grand Junction
RECRUITING
Huntsman Cancer Institute, University of Utah, Salt Lake City
RECRUITING
Stanford University, Palo Alto
RECRUITING
Institute Gustav Roussy, Villejuif
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Vall d'Hebron Barcelona Hospital, Barcelona
RECRUITING
Hospital HM Nou Delfos, Barcelona
RECRUITING
ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona
Tango Therapeutics, Inc.
INDUSTRY